1 ,2 About the REDEFINE 1 trial REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI 30 kg/m 2 ), or overweight (BMI 27 kg/m 2 ) with one or more obesity-related comorbidities, and without type 2 diabetes
Does the Peptide Type Change the Timeline
[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Collins C.P., Longo D.L., Murphy W.J
Section 4 presents the L-PDDOI framework, including label construction, pair prediction, graph repair, transitive reduction, and recovery